Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials

Pharmacotherapy
Boris NogidJamie Dwyer

Abstract

Telavancin and vancomycin are both approved for treatment of hospital-acquired and ventilator-associated bacterial pneumonias caused by Staphylococcus aureus, and both agents can cause renal dysfunction. The objective of this study was to assess renal function changes by performing renal shift table analyses of telavancin- and vancomycin-treated patients in phase III trials. Retrospective, descriptive analysis of data from the safety population from the Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials. A total of 1503 adults with hospital-acquired or ventilator-associated bacterial pneumonia primarily caused by gram-positive pathogens and who received telavancin (n = 751) or vancomycin (n = 752). Decline or improvement in creatinine clearance (CrCl) across seven defined categories (≤30, >30-40, >40-50, >50-60, >60-70, >70-80, and >80 ml/min) was classified as negative or positive shifts, respectively. The number of categories crossed (either positive or negative) determined the grade of shift (of a potential grades 1-6, with crossing from one category to the next adjacent category defined as a grade 1 shift) at specific time points compared with baseline: day 4, day 7, and end of therapy (EO...Continue Reading

References

Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Stanton L GersonDavid J Kuter
Oct 2, 2004·Kidney International·Ravindra L MehtaUNKNOWN Program to Improve Care in Acute Renal Disease
Jan 18, 2005·Chest·Nieves SopenaUNKNOWN Neunos 2000 Study Group
May 18, 2005·The Journal of Infectious Diseases·Jared A SilvermanJeff Alder
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Jul 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano
Mar 20, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Wieneke Marleen MichelsRaymond Theodorus Krediet
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ethan RubinsteinUNKNOWN ATTAIN Study Group
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuUNKNOWN Infectious Diseases Society of America
Sep 14, 2011·Antimicrobial Agents and Chemotherapy·Thomas P LodiseKeith A Rodvold
Jan 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard G WunderinkJean Chastre
Mar 29, 2014·The New England Journal of Medicine·Shelley S MagillUNKNOWN Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team
Jun 27, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Prabha ViswanathanSumathi Nambiar
Sep 16, 2014·Pharmacotherapy·Joseph J CarrenoBen Lomaestro
Feb 26, 2015·Antimicrobial Agents and Chemotherapy·Vincent H TamLuan D Truong
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Melinda K LacySteven L Barriere
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Jan 24, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R E MendesR K Flamm
Jul 4, 2017·Diagnostic Microbiology and Infectious Disease·Debora SweeneyChris M Pillar
Jul 25, 2017·Journal of Global Antimicrobial Resistance·Leonard R DuncanRodrigo E Mendes

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00107952
NCT00124020

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.